|
1
|
Mackay J, Jemal A, Lee NC and Parkin DM:
The Cancer Atlas. American Cancer Society; Atlanta, GA: pp.
2006
|
|
2
|
Anderson BO, Yip CH, Ramsey SD, Bengoa R,
Braun S, Fitch M, Groot M, Sancho-Garnier H and Tsu VD: Breast
cancer in limited-resource countries: health care systems and
public policy. Breast J. 12:S54–S69. 2006.PubMed/NCBI
|
|
3
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar
|
|
4
|
Parkin DM and Fernández LM: Use of
statistics to assess the global burden of breast cancer. Breast J.
12:S70–S80. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sachdev D: Regulation of breast cancer
metastasis by IGF signaling. J Mammary Gland Biol Neoplasia.
13:431–441. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Achen MG and Stacker SA: Tumor
lymphangiogenesis and metastatic spread - new players begin to
emerge. Int J Cancer. 119:1755–1760. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ward CW, Garrett TP, McKern NM, Lou M,
Cosgrove LJ, Sparrow LG, Frenkel MJ, Hoyne PA, Elleman TC, Adams
TE, et al: The three dimensional structure of the type I
insulin-like growth factor receptor. Mol Pathol. 54:125–132. 2001.
View Article : Google Scholar
|
|
8
|
Baserga R, Peruzzi F and Reiss K: The
IGF-1 receptor in cancer biology. Int J Cancer. 107:873–877. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shimizu C, Hasegawa T, Tani Y, Takahashi
F, Takeuchi M, Watanabe T, Ando M, Katsumata N and Fujiwara Y:
Expression of insulin-like growth factor 1 receptor in primary
breast cancer: immunohistochemical analysis. Hum Pathol.
35:1537–1542. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Taunk NK, Goyal S, Moran MS, Yang Q,
Parikh R and Haffty BG: Prognostic significance of IGF-1R
expression in patients treated with breast-conserving surgery and
radiation therapy. Radiother Oncol. 96:204–208. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Casa AJ, Dearth RK, Litzenburger BC, Lee
AV and Cui X: The type I insulin-like growth factor receptor
pathway: a key player in cancer therapeutic resistance. Front
Biosci. 13:3273–3287. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Takeshita F and Ochiya T: Therapeutic
potential of RNA interference against cancer. Cancer Sci.
97:689–696. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Brummelkamp TR, Bernards R and Agami R: A
system for stable expression of short interfering RNAs in mammalian
cells. Science. 296:550–553. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Brummelkamp TR, Bernards R and Agami R:
Stable suppression of tumorigenicity by virus-mediated RNA
interference. Cancer Cell. 2:243–247. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Elbashir SM, Harborth J, Lendeckel W,
Yalcin A, Weber K and Tuschl T: Duplexes of 21-nucleotide RNAs
mediate RNA interference in cultured mammalian cells. Nature.
411:494–498. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rubinson DA, Dillon CP, Kwiatkowski AV,
Sievers C, Yang L, Kopinja J, Rooney DL, Zhang M, Ihrig MM, McManus
MT, et al: A lentivirus-based system to functionally silence genes
in primary mammalian cells, stem cells and transgenic mice by RNA
interference. Nat Genet. 33:401–406. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Addgene, Inc. http://www.addgene.org/11795/.
Accessed March 15, 2012
|
|
18
|
Fang J, Zhou Q, Shi XL and Jiang BH:
Luteolin inhibits insulin-like growth factor 1 receptor signaling
in prostate cancer cells. Carcinogenesis. 28:713–723. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Patel BB, Gupta D, Elliott AA, Sengupta V,
Yu Y and Majumdar AP: Curcumin targets FOLFOX-surviving colon
cancer cells via inhibition of EGFRs and IGF-1R. Anticancer Res.
30:319–325. 2010.PubMed/NCBI
|
|
20
|
Santen RJ, Fan P, Zhang Z, Bao Y, Song RX
and Yue W: Estrogen signals via an extra-nuclear pathway involving
IGF-1R and EGFR in tamoxifen-sensitive and -resistant breast cancer
cells. Steroids. 74:586–594. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Werner H and Bruchim I: The insulin-like
growth factor-I receptor as an oncogene. Arch Physiol Biochem.
115:58–71. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nagy P, Arndt-Jovin DJ and Jovin TM: Small
interfering RNAs suppress the expression of endogenous and
GFP-fused epidermal growth factor receptor (erbB1) and induce
apoptosis in erbB1-overexpressing cells. Exp Cell Res. 285:39–49.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lann D and LeRoith D: The role of
endocrine insulin-like growth factor-I and insulin in breast
cancer. J Mammary Gland Biol Neoplasia. 13:371–379. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Samani AA, Yakar S, LeRoith D and Brodt P:
The role of the IGF system in cancer growth and metastasis:
overview and recent insights. Endocr Rev. 28:20–47. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Reinmuth N, Fan F, Liu W, Parikh AA,
Stoeltzing O, Jung YD, Bucana CD, Radinsky R, Gallick GE and Ellis
LM: Impact of insulin-like growth factor receptor-I function on
angiogenesis, growth, and metastasis of colon cancer. Lab Invest.
82:1377–1389. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Scotlandi K, Maini C, Manara MC, Benini S,
Serra M, Cerisano V, Strammiello R, Baldini N, Lollini PL, Nanni P,
et al: Effectiveness of insulin-like growth factor I receptor
antisense strategy against Ewing’s sarcoma cells. Cancer Gene Ther.
9:296–307. 2002.PubMed/NCBI
|
|
27
|
Mallikarjuna K, Pushparaj V, Biswas J and
Krishnakumar S: Expression of insulin-like growth factor receptor
(IGF-1R), c-Fos, and c-Jun in uveal melanoma: an
immunohistochemical study. Curr Eye Res. 31:875–883. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Girnita A, All-Ericsson C, Economou MA,
Aström K, Axelson M, Seregard S, Larsson O and Girnita L: The
insulin-like growth factor-I receptor inhibitor picropodophyllin
causes tumor regression and attenuates mechanisms involved in
invasion of uveal melanoma cells. Clin Cancer Res. 12:1383–1391.
2006. View Article : Google Scholar
|
|
29
|
Cunnick GH, Jiang WG, Gomez KF and Mansel
RE: Lymphangiogenesis and breast cancer metastasis. Histol
Histopathol. 17:863–870. 2002.PubMed/NCBI
|
|
30
|
Kucab JE and Dunn SE: Role of IGF-1R in
mediating breast cancer invasion and metastasis. Breast Dis.
17:41–47. 2003.PubMed/NCBI
|
|
31
|
Achen MG, McColl BK and Stacker SA: Focus
on lymphangiogenesis in tumor metastasis. Cancer Cell. 7:121–127.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tang Y, Zhang D, Fallavollita L and Brodt
P: Vascular endothelial growth factor C expression and lymph node
metastasis are regulated by the type I insulin-like growth factor
receptor. Cancer Res. 63:1166–1171. 2003.PubMed/NCBI
|
|
33
|
Gu Y, Qi X and Guo S: Lymphangiogenesis
induced by VEGF-C and VEGF-D promotes metastasis and a poor outcome
in breast carcinoma: a retrospective study of 61 cases. Clin Exp
Metastasis. 25:717–725. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Björndahl M, Cao R, Nissen LJ, Clasper S,
Johnson LA, Xue Y, Zhou Z, Jackson D, Hansen AJ and Cao Y:
Insulin-like growth factors 1 and 2 induce lymphangiogenesis in
vivo. Proc Natl Acad Sci USA. 102:15593–15598. 2005.PubMed/NCBI
|
|
35
|
Zhu C, Qi X, Chen Y, Sun B, Dai Y and Gu
Y: PI3K/Akt and MAPK/ERK1/2 signaling pathways are involved in
IGF-1-induced VEGF-C upregulation in breast cancer. J Cancer Res
Clin Oncol. 137:1587–1594. 2011. View Article : Google Scholar : PubMed/NCBI
|
